移植肿瘤学在原发性肝癌与转移性肝病中的兴起
本综述探讨移植肿瘤学在肝细胞癌、结直肠癌肝转移、神经内分泌肿瘤肝转移及肝内和肝门部胆管癌中的应用,重点分析扩大入选标准、优化供器官使用及改善肿瘤学结局的策略,指出严格选择和多模式治疗可改善生存并减少复发。
要点
- 严格选择和多模式治疗下,肝移植可改善 selected 肝癌患者生存并减少复发。
- 降期治疗(局部和全身方案)有助于满足移植标准并影响预后。
- 供器官利用创新策略可扩大移植物池,支持安全扩展适应证。
核心结论
- 移植肿瘤学重塑肝恶性肿瘤治疗格局, growing evidence 支持在严格选择的传统适应证之外患者中行肝移植。
- 优化降期、创新供器官策略和个体化免疫抑制对安全扩展至关重要。
研究设计与样本
- 综述,综合临床系列、登记处和实验方案证据,评估患者选择标准、结局及围移植管理。
主要发现
- 应用严格选择和多模式治疗时,报告的研究显示生存改善且复发减少。
- 降期方法包括局部区域治疗和全身方案,其预后意义被讨论。
- 供器官利用进展被分析用于扩大移植物池的能力。
关键数值与推荐
- 肝移植应用于肝细胞癌、结直肠癌肝转移、神经内分泌肿瘤肝转移及肝内和肝门部胆管癌。
- 降期方法包括局部区域治疗和全身方案,用于满足移植标准。
临床怎么用
- 在严格选择的肝恶性肿瘤患者中考虑肝移植,并结合降期和多模式治疗。
- 整合肿瘤学原则于免疫抑制方案,平衡移植物保护与肿瘤控制。
局限性
- 需移植与肿瘤学科持续合作及前瞻性试验以定义标准化方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Liver transplantation has evolved from a treatment restricted to patients with end-stage liver disease to a therapeutic option for selected patients with primary and metastatic liver malignancies. This review explores the rapidly expanding field of transplant oncology, highlighting its role in hepatocellular carcinoma, colorectal liver metastasis, neuroendocrine liver metastasis, and intrahepatic and perihilar cholangiocarcinoma. Emphasis is placed on strategies to broaden eligibility, optimize donor organ use, and improve oncologic outcomes. APPROACH AND RESULTS: We synthesized current evidence from clinical series, registries, and experimental protocols to evaluate patient selection criteria, outcomes, and peri-transplant management. Key topics include downstaging approaches to meet transplant criteria, such as locoregional therapies and systemic regimens, and their prognostic implications. Advances in donor utilization have been analyzed for their capacity to expand the graft pool. In addition, the review addresses the integration of oncologic principles into immunosuppression regimens, balancing graft protection with cancer control. Collectively, the reported studies demonstrate improved survival and reduced recurrence when stringent selection and multimodal therapy were applied. CONCLUSIONS: Transplant oncology reshapes the therapeutic landscape of liver malignancies, with growing evidence supporting liver transplantation in carefully selected patients beyond traditional indications. Optimized downstaging, innovative donor strategies, and tailored immunosuppression are pivotal for safe expansion. Continued collaboration between the transplant and oncology disciplines, along with prospective trials, is essential to further define standardized protocols and solidify transplantation as a cornerstone of multidisciplinary cancer care.
引用
- Wassmer CH, Gelli M, Wong TCL, et al. The rise of transplant oncology in primary liver cancer and metastatic disease. Hepatology. 2026. PMID: 41746604. doi:10.1097/HEP.0000000000001723
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。